Abstract Objective: To compare the efficacy and safety of telitacicept as add-on therapy versus standard of care (SOC) alone in immunosuppressant (IS)-naïve patients with lupus nephritis (LN) and in patients with refractory LN. Methods: In this bicentric, real-world, retrospective, triple-cohort study, we enrolled IS-naïve LN patients receiving add-on telitacicept (Cohort 1), IS-naïve LN patients receiving SOC alone (Cohort 2), and refractory LN patients receiving add-on telitacicept (Cohort 3).
Jinhai Chen
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Jinhai
Contact Jinhai, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack